DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

• In the Phase 3 VITESSE study, VIASKIN Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic condition, including asthma, concomitant food allergy, or atopic dermatitis.
• DBV will also present the clinical trial design of its recently initiated THRIVE study, which will assess the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib consumption of peanuts in infants ages 6 through 12 months with peanut allergy following three years of treatment.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced new positive data from its Phase 3 VITESSE study of the VIASKIN Peanut Patch in children ages 4 through 7 years with peanut allergy, and a preview of the design of its Phase 2 THRIVE study in infants ages 6 through 12 months with peanut allergy. Both will be presented in oral abstract sessions at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, taking place June 12 – 15, 2026 in Istanbul, Turkey.

“The presentation of these two abstracts at EAACI underscores the versatility and clinical value of the VIASKIN Peanut Patch program across a range of patient populations,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “From infants as young as 6 through 12 months, where early intervention may help shape long-term outcomes, to children ages 4 through 7 years with peanut allergy and common conditions like asthma, other food allergies and atopic dermatitis, we are committed to developing treatment options that can help meet patients and caregivers wherever they are in their peanut allergy journey. The VITESSE results in children with other common atopic conditions further strengthen our confidence in the potential clinical value of the VIASKIN Peanut Patch. We believe the VIASKIN Peanut Patch has the potential to offer a proactive, non-invasive, patient-centric approach to peanut allergy management, if approved.”

Schreibe Deinen Kommentar